185 related articles for article (PubMed ID: 35666070)
1. Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US.
Leung J; Anderson TC; Dooling K; Xie F; Curtis JR
Arthritis Rheumatol; 2022 Nov; 74(11):1833-1841. PubMed ID: 35666070
[TBL] [Abstract][Full Text] [Related]
2. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
Fix J; Vielot NA; Lund JL; Weber DJ; Smith JS; Hudgens MG; Becker-Dreps S
Vaccine; 2023 Jan; 41(1):49-60. PubMed ID: 36396511
[TBL] [Abstract][Full Text] [Related]
3. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
[TBL] [Abstract][Full Text] [Related]
4. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.
Janusz CB; Anderson TC; Leidner AJ; Lee GM; Dooling K; Prosser LA
Hum Vaccin Immunother; 2022 Nov; 18(5):2060668. PubMed ID: 35476029
[TBL] [Abstract][Full Text] [Related]
5. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
Leung J; Gray EB; Anderson TC; Sharkey SM; Dooling K
Vaccine; 2022 Nov; 40(50):7187-7190. PubMed ID: 36347721
[TBL] [Abstract][Full Text] [Related]
6. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
[TBL] [Abstract][Full Text] [Related]
7. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
8. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
Parikh R; Singer D; Chmielewski-Yee E; Dessart C
Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
[TBL] [Abstract][Full Text] [Related]
10. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
[TBL] [Abstract][Full Text] [Related]
11. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
[TBL] [Abstract][Full Text] [Related]
12. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
[TBL] [Abstract][Full Text] [Related]
13. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
[TBL] [Abstract][Full Text] [Related]
14. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
[TBL] [Abstract][Full Text] [Related]
15. Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
Lewis CY; Mishra K; Sun Y; Sechrist SJ; Arnold BF; Acharya NR
Vaccine; 2023 May; 41(23):3493-3496. PubMed ID: 37150621
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
[TBL] [Abstract][Full Text] [Related]
17. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
[TBL] [Abstract][Full Text] [Related]
18. Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination.
Walia A; Sun Y; Acharya NR
JAMA Ophthalmol; 2024 Mar; 142(3):249-256. PubMed ID: 38358762
[TBL] [Abstract][Full Text] [Related]
19. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
Min JY; Mwakingwe-Omari A; Riley M; Molo LY; Soni J; Girard G; Danier J
J Infect; 2022 Apr; 84(4):490-498. PubMed ID: 34963639
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Zoster Vaccine [RZV] is Effective in Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study.
Desai A; Hashash JG; Kochhar GS; Hayney MS; Caldera F; Farraye FA
J Crohns Colitis; 2024 Jun; 18(6):828-835. PubMed ID: 38224526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
